HilleVax (NASDAQ:HLVX) Cut to “Market Perform” at SVB Leerink

SVB Leerink downgraded shares of HilleVax (NASDAQ:HLVX) from an outperform rating to a market perform rating in a research report report published on Tuesday morning, MarketBeat Ratings reports. SVB Leerink currently has $2.00 price objective on the stock, down from their prior price objective of $28.00.

A number of other equities analysts also recently issued reports on HLVX. HC Wainwright restated a neutral rating and issued a $2.00 price target (down from $28.00) on shares of HilleVax in a research note on Tuesday. JPMorgan Chase & Co. restated a neutral rating and issued a $5.00 price target (down from $24.00) on shares of HilleVax in a research note on Monday. Stifel Nicolaus downgraded HilleVax from a buy rating to a hold rating and dropped their price target for the stock from $34.00 to $3.00 in a research note on Tuesday. Finally, Guggenheim downgraded HilleVax from a buy rating to a neutral rating in a research note on Monday. Six analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has an average rating of Hold and an average target price of $9.20.

HilleVax Stock Performance

Shares of HLVX opened at $1.67 on Tuesday. The business’s fifty day simple moving average is $12.80 and its two-hundred day simple moving average is $14.50. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. HilleVax has a 12 month low of $1.55 and a 12 month high of $20.22. The company has a market cap of $83.03 million, a price-to-earnings ratio of -0.51 and a beta of 0.78.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.13). Research analysts anticipate that HilleVax will post -3.14 earnings per share for the current fiscal year.

Insider Activity at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $15.45, for a total transaction of $92,700.00. Following the sale, the director now directly owns 776,878 shares of the company’s stock, valued at $12,002,765.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 12,898 shares of company stock worth $193,766. Corporate insiders own 71.10% of the company’s stock.

Institutional Investors Weigh In On HilleVax

Large investors have recently made changes to their positions in the company. EntryPoint Capital LLC bought a new stake in shares of HilleVax in the first quarter worth about $80,000. SG Americas Securities LLC purchased a new stake in shares of HilleVax in the fourth quarter valued at approximately $139,000. Tidal Investments LLC purchased a new stake in shares of HilleVax in the first quarter valued at approximately $207,000. abrdn plc bought a new position in HilleVax in the fourth quarter worth approximately $433,000. Finally, Swiss National Bank raised its stake in HilleVax by 22.4% in the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after buying an additional 7,000 shares in the last quarter. 86.42% of the stock is owned by institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.